GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis
Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination With Methotrexate, Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Thr ...